Two of the major powers in the use of CRISPR-Cas9 in agriculture have reached a surprising arrangement that could accelerate the creation of genome-edited crops, giving companies a way to more easily license the intellectual property they need to make drought- or bug-resistant plants without worrying about being sued for patent infringement.

The agreement, announced on Wednesday and in effect immediately, is between the Broad Institute of MIT and Harvard, which holds dozens of key (but disputed) patents on the CRISPR genome-editing technology, and DuPont Pioneer, a major producer of genetically modified seeds. Pioneer licensed exclusive rights to agricultural uses of CRISPR from Caribou Biosciences, a spinoff of the University of California, Berkeley, and a second company, ERS Genomics. UC, Caribou, and ERS are allied in a heated patent fight against the Broad.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy